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Abstract
Candidate polymorphism-based genetic epidemiological studies
have yielded little success in the search for low-penetrance breast
cancer susceptibility genes. The lack of progress is partially due to
insufficient coverage of genomic regions with genetic markers, as
well as economic constraints, limiting both the number of genetic
targets and the number of individuals being studied. Recent rapid
advances in high-throughput genotyping technology and our
understanding of genetic variation patterns across the human
genome are now revolutionizing the way in which genetic
epidemiological studies are being designed and conducted.
Genetic epidemiological studies are quickly progressing from
candidate gene studies to comprehensive pathway investigation
and, further, to genomic epidemiological studies where the whole
human genome is being interrogated to identify susceptibility
alleles. This paper reviews the evolving approaches in the search
for low-penetrance breast cancer susceptibility gene variants and
discusses their potential promises and pitfalls.
Introduction
Family history is a well-established risk factor for breast
cancer. Breast cancer risk is typically increased by two- to
three-fold in first-degree relatives of affected individuals.
Mutations in high-penetrance cancer susceptibility genes
such as BRCA1 and BRCA2 account for less than 20% of
the excess familial risk [1]. The remaining familial risk is likely
to be explained by a polygenic model where breast cancer
susceptibility is conferred by a large number of low-
penetrance alleles. The risk conferred by each of these alleles
may be small but these alleles may combine additively or
multiplicatively to affect breast cancer susceptibility
substantially [2]. Rare, high-penetrance susceptibility alleles
have been successfully mapped using family-based linkage
studies. Further progress in the search for genetic
determinants of breast cancer likely lies in the identification of
the large number of low-penetrance cancer susceptibility
alleles by population-based genetic association studies.
Numerous genetic association studies on breast cancer have
been published but results have been equivocal, partly due to
shortcomings in study design [3]. The past few years have
witnessed rapid advances in high-throughput technologies
for genotyping analysis as well as in our understanding of
genetic variation patterns across the human genome. These
advances have empowered researchers to improve the
design of genetic epidemiological studies, especially the way
in which genetic variation is captured. In this short review, we
will focus on the recent developments in high-throughput
technologies for genotyping analysis and their impact on
genetic epidemiological studies of breast cancer, addressing
both their promises and pitfalls.
Candidate polymorphism analysis
The genetic association studies published on breast cancer
from the 1990s onwards have typically compared the allelic
and/or genotypic frequencies of selected polymorphisms
between breast cancer cases and controls. These studies
aimed to find polymorphisms that may be directly related to
breast cancer risk as causal variants or indirectly related to
breast cancer risk due to being in linkage disequilibrium (LD)
with causal variants. These studies typically start with the
selection of candidate genes based on current biological
understanding of their potential role in breast cancer
carcinogenesis. Then a small number of polymorphisms are
selected in these genes and genotyped. Polymorphism
selection has usually been based on isolated reports of a
polymorphism’s potential functional effect, such as coding
variants, and/or its feasibility to be successfully genotyped at
that time.
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Moving from family-based linkage studies to population-
based genetic association analysis causes a shift from
microsatellite markers to single nucleotide polymorphisms
(SNPs) as the leading marker for genetic analysis. Micro-
satellite markers have been extremely useful in mapping
causal genetic variants in family pedigrees and have been
successfully used to identify high-penetrance genes, as in the
case of BRCA1 [4]. But microsatellite markers are less
efficient in population-based genetic association analysis and
have rarely been used in the search for low-penetrance alleles
using unrelated subjects [5,6], partly due to their relatively
high mutation rate and complex mutation patterns. Compared
to microsatellite markers, SNPs are stable, more abundant,
associated with lower genotyping error, easier to automate
and thus cheaper in terms of cost and labor. The availability of
detailed information on LD patterns of SNPs has also
enabled genetic variation to be captured more effectively
using SNPs. Hence, SNPs have increasingly dominated the
field of population-based genetic association studies in
breast cancer. Examples of genes investigated using
candidate SNPs include the steroid hormone metabolism
genes (CYP17, CYP19, COMT, SHBG), estrogen-signaling
genes (ESR1, ESR2), carcinogen metabolism genes (CYP1A1,
NAT1,  NAT2,  GSTM1) and DNA repair genes (XRCC1-3,
ATM) [7-9]. Although being commonly termed candidate
gene analysis, such studies can at most qualify as candidate
polymorphism analysis since only a very small number of
polymorphisms within each gene were evaluated and these
cannot be assumed to represent the whole gene, especially if
the gene is large.
Despite huge efforts being invested in population-based
genetic association studies of breast cancer, the outcome
has not been satisfactory. The low throughput and high cost
of genotyping analysis has constrained investigators to
studying only a few polymorphisms within a few candidate
genes in a limited number of samples. Positive results have
been rare and often not replicated in subsequent studies. It is
possible that the generally negative findings of past studies
may be due to a true absence of risk alleles of moderate to
high effect for breast cancer. But given both poor coverage
and inadequate power of past studies, causal alleles are likely
to be missed even if they exist. Hence negative results of
such studies could not be used as evidence to rule out the
role of a particular gene in breast cancer risk. To illustrate the
problem of inadequate power, a systematic review of genetic
association studies of breast cancer found 46 case-control
studies published between 1983 and July 1998. Most
studies were small, with the median number of cases and
controls combined being 391 (range 58 to 1,431). From
power calculations, a study of 315 cases and 315 controls
will be needed to detect a risk allele with a frequency of 20%
conferring a relative risk of 2.5 with 90% power at the 5%
significance level. Only 10 out of 46 studies met these
criteria [8]. It has been further argued that to reduce false
positives arising from multiple testing, a significance level of
10–4 should be used for candidate gene studies. Then a
study of approximately 1,000 cases and 1,000 controls will
be needed to detect a susceptibility allele with a frequency of
20% conferring a relative risk of 1.5 [10]. Few candidate
polymorphism studies in breast cancer have managed to fulfill
such criteria. In summary, limited progress has been made by
such candidate polymorphism-based genetic epidemiological
studies in identifying low-penetrance risk alleles for breast
cancer.
Recent developments in high-throughput
genotyping technology
The rapid development of high-throughput technology for
SNP genotyping over the past few years has resulted in a
wide variety of SNP genotyping platforms now available for
use, each with unique features. On platforms such as the
Illumina BeadArray™ and the Affymetrix GeneChip® array
systems, up to thousands of SNPs can be analyzed
simultaneously (i.e., multiplexed) in each sample. These have
dramatically increased the throughput of genotyping and
brought down the genotyping cost per SNP. Such platforms
are well suited for large-scale screening studies where
thousands of SNPs are analyzed in a fair number of samples.
However, due to their high level of multiplexing, total cost,
and sometimes lengthy process of initial assay development,
these platforms become unwieldy in studies where only a
moderate number of SNPs needs to be analyzed. For such
studies, Sequenom’s MassARRAY® system is one of the
better choices as it only requires up to 29 SNPs for each
multiplexing assay and requires short assay development time
by investigators themselves. Such systems provide greater
flexibility and efficiency for investigators to carry out either
medium-size studies that target a moderate number of
candidate genes or follow-up studies where a limited number
of positive findings from initial large-scale screening studies
are further investigated in large samples. In situations where
only single or a very limited number of SNPs need to be
analyzed in a large number of samples (e.g., in confirmation
studies), methods such as TaqMan® and Pyrosequencing™
assays are more suitable. Such systems can only genotype
very few SNPs at a time but are very robust and efficient. A
summary of the main features of some of the main genotyping
platforms available for custom SNPs is shown in Table 1. A
detailed discussion of SNP genotyping technology is beyond
the scope of this review but has been reviewed elsewhere
[11-13].
The technological limit of genotyping analysis has been
further challenged by the recent release of ultra high-
throughput systems from Illumina and Affymetrix. Innovative
multiplexing chemistry allows these systems to analyze
between approximately 317,000 SNPs (Illumina’s Sentrix®
humanHap300 beadchip and Infinium™ II assay) and
500,000 SNPs (Affymetrix’s GeneChip® Mapping 500K
Array) in a single experiment. Both systems are of fixed
contents, meaning that all the SNPs for analysis have beenPage 3 of 6
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pre-selected by the manufacturers. While Illumina’s SNP
selection is based on the available information on allele
frequency and the LD pattern of the human genome from the
HapMap project, Affymetrix’s SNP selection is generally
random and mainly based on the SNPs’ feasibility to be
genotyped. By driving down the genotyping cost below
US$0.01 per SNP, such systems have transformed whole-
genome association analysis into reality.
The technological advancements in genotyping analysis,
coupled with the extensive collection of validated SNPs and
knowledge of LD patterns across the human genome from
the HapMap project, have transformed the landscape of
genetic epidemiological studies. These advancements have
allowed us to progress from the investigation of candidate
polymorphisms to truly comprehensive candidate gene and
whole-genome studies.
Comprehensive candidate gene study using
the haplotype tagging approach
Knowledge of LD patterns across different genes has given
rise to the haplotype tagging approach as an efficient way of
conducting comprehensive candidate gene studies. Due to
the extensive non-independence between SNPs and the
limited haplotype diversity within regions of strong LD (LD
blocks) in the human genome, only a subset of selected
SNPs, instead of all variants, needs to be analyzed to capture
the majority of common genetic variation within such blocks.
With an average LD block size of between 11 and 22 kb and
assuming 3 to 5 haplotypes per block, it has been estimated
that around 300,000 to 1,000,000 well-chosen tagging
SNPs (in non-African and African samples, respectively)
would be required to capture the 10 million SNPs that are
thought to exist [14]. Equipped with large sample sizes and
efficient coverage of all genetic variation within candidate
genes, current genetic epidemiological studies are expected
to stand a good chance of detecting susceptibility alleles with
moderate effects, if they exist. While current genetic associa-
tion studies are being geared up to a comprehensive
coverage of common variants and are thus greatly enhancing
the confidence of a negative result, it will be difficult to
assertively exclude the role of a candidate gene purely based
on the results of LD mapping. Although there is general
agreement on the merits of using the haplotype tagging
approach in genetic association studies, there are pitfalls
[15] and active discussions are still ongoing on several
issues, including optimizing tagging SNP selection [16,17] and
haplotype construction [18], as well as statistical analysis of
such SNP/haplotype data to study disease associations [19].
Genetic association studies on breast cancer that have used
haplotype tagging SNPs for candidate gene analysis are
starting to appear in the literature. Some examples of genes
studied in this manner include CYP19 [20], HSD17B1 [21],
EMSY [22] and CHEK2 [23], and more results are expected
in the near future. Currently, published studies have focused
on assessing genetic variation within single candidate genes,
but more efforts will be needed to evaluate entire biological
pathways or gene families. Genes often work together as part
of complex biological pathways. Selecting a single candidate
gene within a pathway for genetic epidemiological investiga-
tion is likely to be over-simplistic. Instead, genetic variability of
entire biological pathways, for example, the estrogen
metabolism pathway, should be investigated to evaluate
potential association with disease. Although it is no longer
technologically challenging to capture most, if not all, of the
Available online http://breast-cancer-research.com/content/8/3/209
Table 1
Main features of some custom SNP genotyping platforms available
Throughput Cost  per 
(no. of samples  genotype (at 
Multiplexing  per 8 hour  maximal  Type of study design that 
Assay design capability working day) multiplexing)a platform is suitable for 
TaqMan® By manufacturer or flexible  No Up to 10,000+  >US$0.30 Small number of SNPs, 
design by investigator  large sample size
Pyrosequencing™ Flexible design by  From 1 to 3 Up to 4,000+ >US$0.30 Small number of SNPs, 
investigator  large sample size
Sequenom  Flexible design by  From 1 to  Up to 3,000+  US$0.05-0.10 Moderate number of SNPs, 
MassARRAY® investigator 29-plex small/moderate sample size
Illumina BeadArray™  By manufacturer From 96 to  Up to 192 <US$0.05 Large number of SNPs, 
(GoldenGate® Assay) 1,536-plex small/moderate/large 
sample size
Affymetrix GeneChip® By manufacturer From 1,500 to  Up to 16 <US$0.05 Large number of SNPs, 
20,000-plex small/moderate/large 
sample size
aThe estimates are heavily influenced by the size of study, that is, large studies will enjoy more efficient usage of reagents and volume-based price
discount from manufacturers than medium and small studies. SNP, single nucleotide polymorphism.common genetic variation within a biological pathway using
the haplotype tagging approach, the method for data analysis
is not straightforward. Locus-by-locus analysis can detect
SNPs associated with moderate main effects. But this
method of analysis will become less effective in situations
where breast cancer susceptibility is attributed to a fair
number of alleles, each of which is only associated with a
weak effect (below the threshold for detection) or in situa-
tions where susceptibility is attributed to the interaction of
multiple SNPs, each with negligible effect. Therefore,
success of comprehensive candidate gene studies will rely
substantially on the development of new statistical methods
for evaluating the cumulative effect of whole biological
pathways on susceptibility to breast cancer.
Genomic epidemiological studies
The success of candidate gene studies, whether based on
single genes or whole pathways, is constrained by our
current biological understanding of breast carcinogenesis.
Since breast carcinogenesis is a complex and still only
partially understood process, it is likely that many important
genes are overlooked in candidate gene studies. Such a
limitation can only be overcome by genomic epidemiological
studies where no prior biological hypotheses are assumed
and the entire human genome is targeted for identifying
genetic variation associated with breast cancer susceptibility.
Several research groups have embarked on whole genome
association studies in breast cancer but no results have been
published yet. The use of whole genome scans in genetic
association studies is still in its infancy. Design issues for
genome-wide association studies are still evolving and have
been reviewed elsewhere [24,25].
Although promising, genome-wide association studies bring
about major challenges in regard to data analysis. Genetic
epidemiological studies have conventionally been designed in
such a way that a relatively small number of potential risk
factors (both genetic and non-genetic) are evaluated in a
much larger number of samples. Locus-by-locus approaches
for statistical analysis are well developed for such designs to
evaluate the main effect of a genetic variant and simple
interactions between genetic variants. In contrast, genome-
wide association studies are expected to involve analysis of
hundreds of thousands of SNPs in several hundred (or
thousand) samples. This means that the number of testing
targets will be far greater than the number of samples, which
is unfavorable for a conventional locus-by-locus statistical
analysis approach. This issue has already emerged when
attempting to extend the candidate gene approach to
studying multiple genes in a pathway but will become greatly
compounded in the whole genome analysis. By performing a
locus-by-locus test on each of the hundreds of thousands of
SNPs in a moderate sample size, a large number of false
positive findings are expected to be generated in addition to
the expected small number of true positive results. Because
the true risk alleles are likely to be associated with moderate
effects, the true positive association results are by no means
guaranteed to enjoy stronger statistical evidence than the
false positive ones. Although Bonferroni correction or false
discovery rate can be used to control the adverse effect of
multiple testing and reduce the false positive rate, they
cannot improve the power for detection. As a means of
validating initial positive findings, a two-stage design may be
used in which a large number of potential positive findings
from the initial genome-wide analysis are tested in a much
bigger sample. But the efficiency of such a design still needs
to be proven by real studies. Hypothesis-free attempts to
identify interactions among genetic variants at the genomic
level will be even more challenging, due to the immense
number of tests involved. Initial simulation analysis has
demonstrated the feasibility of performing genome-wide
interaction analysis [26], but more will need to be done to
verify its efficiency.
Future directions
Looking ahead, the technical barriers to genotyping are
unlikely to be a limiting factor. Future breakthroughs in the
search for breast cancer susceptibility genes will probably
hinge heavily on devising novel data analysis strategies to
make sense out of the vast amount of data generated.
Although still speculative, novel statistical and/or mathe-
matical approaches that allow the incorporation of the
information of biological network and genomic structure will
likely champion the field of data analysis.
With the vast amount of data generated from high throughput
genotyping, many genetic association findings are expected.
Replication will be needed and functional verification will
need to be conducted to identify true causal alleles. Efforts to
devise efficient methods for functional validation would
accelerate the accumulation of well-founded evidence.
Despite all the promises held by genome-wide association
studies, if such studies are not handled properly, large
numbers of false positive results will be generated and
published. This will result in a significant drain in resources
invested in studies with slim prior probabilities of yielding
significant findings, which would slow down the search for
breast cancer susceptibility genes. Recognizing the promises
and the pitfalls of such genomic approaches, efforts are
already underway to coordinate genetic association studies
to build a roadmap for efficient and effective human genomic
epidemiology [27].
Apart from genetic factors, environmental and lifestyle factors
also play a substantial role in affecting breast cancer risk [28-
30]. Low penetrance genes most likely act in concert with
lifestyle and other environmental factors to affect breast
cancer risk. The subtle effects of some genetic variants may
be magnified and only become detectable in the presence of
certain exposures. Failure to take into account these external
factors may hinder the search for breast cancer susceptibility
gene variants. For example, the associations between
Breast Cancer Research    Vol 8 No 3 Low et al.
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were only detectable in women with a high intake of folate
and carotenoids [31,32]. Studies of such gene-environment
interactions will not only help in the search for low-
penetrance gene variants affecting breast cancer risk, but
can also uncover ways by which risk may be modified.
Finally, it deserves to be mentioned that no amount of
genetic, technological or statistical sophistication can
compensate for a badly devised study. Sound epidemio-
logical design remains fundamental in order to obtain valid
and reproducible genomic epidemiological results. Sufficient
numbers of carefully defined cases and appropriately chosen
controls with accurate information about potential
confounders and effect modifiers are needed. Ideally such
study samples will be derived from large prospective studies.
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Box 1
Glossary of terms
Genetic epidemiology The study of the relationship between 
variation in specific genes and disease 
risk
Genomic epidemiology The study of the relationship between 
variation across the entire human genome 
and disease risk
Haplotype A set of closely linked alleles that tend to 
be inherited together
HapMap project A multi-country effort to identify and 
catalog common genetic variants in 
humans and work out their haplotype 
structures
Linkage disequilibrium The phenomenon that alleles physically 
close to each other tend to be correlated 
and are co-inherited as a block of DNA 
segment
Microsatellite A type of DNA sequence variation where 
there is tandem repetition of a short DNA 
sequence (usually two to four 
nucleotides)
Penetrance  Probability that a deleterious gene variant 
will actually result in disease
Polymorphism Variation in DNA sequence among 
individuals
Single nucleotide  A type of DNA sequence variation in 
polymorphism which a single nucleotide (A, T, C, or G) 
in the genome sequence is alteredcancer: a case-control study using HapMap tagging SNPs.
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